What Biotech Licensing Really Buys
Biotech licensing is often framed as a transaction around intellectual property. The molecule still comes first: if the biology is weak, the target is undifferentiated, or the clinical rationale is unconvincing, no amount of technical discipline will rescue the program.
What it tends to underestimate is a related question: once the rights change hands, how much of an asset’s apparent value will survive not only clinical development but the transfer itself? In biologics, the asset is never just the molecule. It also includes the development system built around it.
In this recent Genetic Engineering & Biotechnology News (GEN) Point of View article, Dr. Kaisong Zhou, Chairman and CEO, and Dr. Sun Chau Siu, Executive Director and Head of Regulatory Affairs and Project Management, explore what often gets overlooked in licensing: the development knowledge, process understanding and technical judgment that determine whether a biologic can be successfully transferred and reproduced by another team.
Read the article on GEN to see our full insights.